Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab

Takeru Wakatsuki,Naoki Ishizuka,Shuichi Hironaka,Keiko Minashi,Shigenori Kadowaki,Masahiro Goto,Hirokazu Shoji,Hidekazu Hirano,Izuma Nakayama,Hiroki Osumi,Mariko Ogura,Keisho Chin,Kensei Yamaguchi,Daisuke Takahari

International Journal of Clinical Oncology（2024）

引用 0|浏览4

暂无评分

摘要

The aim of this study was to explore the clinical utility of serum HER2 extracellular domain (sHER2 ECD) using data from a clinical trial evaluating trastuzumab combined S-1 plus oxaliplatin (SOX) in HER2 positive gastric cancer. sHER2 ECD were prospectively measured at baseline and subsequent treatment courses. Based on each quantile point of baseline sHER2 ECD levels and its early changes, patients were divided into two groups and compared clinical outcomes. 43 patients were enrolled, and 17 patients (39.5

查看译文

关键词

HER2,Serum HER2 ECD,Gastric Cancer,Trastuzumab,Biomarker

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要